I have been involved with Journal of Thoracic Disease for several years now as an author, reviewer, and recently as an associate editor. During such time, I have witnessed how the journal evolved to include international experts in diagnosing as well as managing the leading cause of cancer death i.e. lung cancer. This has given JTD greater visibility across the globe. It continues to be a leading resource for innovation, clinical research as well as updated reviews in the field of thoracic disease. With such clear vision this has led to increase in impact factor due to the great effort the editorial team as well as all staff involved with JTD. I firmly believe that the journal future is bright and carries more collaboration across multiple disciplines for a better management of patient with thoracic diseases across the globe.

JTD has been a great international journal representing so many different countries with different experiences, data, outcomes, and treatment styles that allows readers to get a better depth and breadth of understanding on truly what is cutting edge clinical care and research as it relates to diseases in the chest. It is also a great well rounded journal for cancer and non-cancer topics and is valuable for all different specialties as well. I have enjoyed being both an editorial board member as well as author for JTD articles. In addition, the editorials, commentaries and reviews by JTD members are fantastic.

The Journal of Thoracic Disease offers a dynamic platform to present cutting edge pulmonary and thoracic related research and observations. It is geared for rapid turnaround of submitted manuscripts. It has been a pleasure to work with this up-and-coming journal.

It is with great pride and enthusiasm that I join the Journal of Thoracic Disease (JTD) in celebrating the tremendous growth milestone in earning an impact factor of 1.9 for the year 2024. As a member of the editorial board, I have experienced the journal's dedication, rigor, and collaborative spirit that have propelled JTD to this accomplishment. This reflects the journal’s growing influence and impact in the study of thoracic diseases, and its commitment to advancing science worldwide.

Since the journals inception, JTD has become a vital platform for disseminating cutting-edge research, fostering interdisciplinary collaboration, and addressing thoracic challenges in an open-access form available to all. I am particularly proud of our collective efforts to maintain rigorous peer review and amplify diverse ideas from researchers and clinicians worldwide.

Looking ahead, I envision JTD to continue this momentum. The rapid evolution of artificial intelligence and emerging technologies will be an area to focus on in future issues of JTD. As the journal grows, it remains important that we continue to support early-career researchers with mentorship and publication opportunities.

I extend my heartfelt gratitude to our authors, reviewers, editorial team, and readers for their invaluable contributions. Reflecting on past performances, I am assured that JTD can continue to shape the exciting future of thoracic surgery and medicine.

Congratulations on AES’s First Impact Factor!

It is with great joy and admiration that I congratulate Annals of Eye Science on achieving its very first impact factor of 1.1. This milestone is not only a remarkable achievement for the journal itself, but also a reflection of the dedication, vision, and tireless efforts of the entire editorial team, reviewers, and contributors who have worked passionately to establish AES as a respected platform in the field of ophthalmology.

The journal’s rapid progress and growing reputation highlight its crucial role in fostering academic exchange, inspiring innovation, and advancing excellence in eye science and clinical practice. With its strong foundation and commitment to quality, I am confident that AES will continue to flourish and further strengthen its influence within the global scientific community.

I am truly honored to be part of the AES journey and look forward to witnessing many more milestones ahead. My warmest congratulations once again to the editors, authors, and readers of AES—may this be only the first of many achievements to come!

Congratulations on AES achieving an Impact Factor of 1.1 and a CiteScore of 1.6 for the year 2024, ranking 85th among 141 ophthalmological journals.

This remarkable accomplishment is undoubtedly the results of the dedicated efforts of your editorial team and reviewers.

In recent time, a tremendous volume of papers is being disseminated, however, what truly matters is the quality of the publications. I sincerely hope that AES will continue to contribute meaningfully to the advancement of ophthalmological knowledge and the improvement of eye care worldwide.